

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI147044

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
Zevra Therapeutics Inc. (as successor in interest to Nantahala Capital Management, LLC, as successor in interest to SWK Funding LLC)	04/05/2024

RECEIVING PARTY DATA

Company Name:	Acer Therapeutics Inc.
Street Address:	One Gateway Center, Suite 351
Internal Address:	300 Washington Street
City:	Newton
State/Country:	MASSACHUSETTS
Postal Code:	02458

PROPERTY NUMBERS Total: 38

Property Type	Number
Application Number:	13386549
Application Number:	14745205
Application Number:	15320952
Application Number:	15653155
Application Number:	16114661
Application Number:	16134558
Application Number:	16156124
Application Number:	16676030
Application Number:	16718343
Application Number:	16740131
Application Number:	16746186
Application Number:	16779132
Application Number:	16879511
Application Number:	16930208
Application Number:	17196416
Application Number:	17196599
Application Number:	17542165
Application Number:	61228485
Application Number:	62308614

PATENT

Property Type	Number
Application Number:	63048892
Application Number:	63059062
Application Number:	63059086
Application Number:	63065272
Application Number:	63121743
Application Number:	63134542
Application Number:	63173098
Application Number:	63218211
Application Number:	63232011
Application Number:	63305207
Application Number:	63305209
Application Number:	63306215
Application Number:	63306216
PCT Number:	US1657415
PCT Number:	US2124399
PCT Number:	US2140760
PCT Number:	US2144016
PCT Number:	US2144018
PCT Number:	US2161867

CORRESPONDENCE DATA

Fax Number: 7043311159

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (704)331-1000

Email: vangambrell@mvalaw.com,jansnider@mvalaw.com

Correspondent Name: JAMES VAN CLEAVE GAMBRELL

Address Line 1: Moore & Van Allen PLLC

Address Line 2: 100 North Tryon Street, Suite 4700

Address Line 4: Charlotte, NORTH CAROLINA 28202

ATTORNEY DOCKET NUMBER:	050487.000004
NAME OF SUBMITTER:	Jan Snider
SIGNATURE:	Jan Snider
DATE SIGNED:	04/05/2024

Total Attachments: 18

source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page1.tif

source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page2.tif

source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page3.tif

source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page4.tif

source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page5.tif

source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page6.tif
source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page7.tif
source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page8.tif
source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page9.tif
source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page10.tif
source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page11.tif
source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page12.tif
source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page13.tif
source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page14.tif
source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page15.tif
source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page16.tif
source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page17.tif
source=Zevra Financing - IP Collateral Release (Acer) (Executed)#page18.tif

**TERMINATION AND RELEASE
OF SECURITY INTEREST**

April 5, 2024

This TERMINATION AND RELEASE OF SECURITY INTEREST (the “Release”) is executed as of the date hereof, by ZEVRA THERAPEUTICS, INC., a Delaware corporation (“Zevra”), in favor of ACER THERAPEUTICS INC., a Delaware corporation (“Borrower”).

WHEREAS, ACER THERAPEUTICS INC., a Delaware corporation (“Borrower”), entered into that certain Credit Agreement (the “Credit Agreement”), dated as of March 4, 2022 and subsequently amended on August 19, 2022, January 30, 2023, and May 12, 2023, with SWK FUNDING LLC, a Delaware limited liability company (“SWK”), and the lenders party thereto, wherein SWK was the agent of such lenders, which provided for a term loan to Borrower (the “Loan”). The Credit Agreement, together with any Notes (as defined in the Credit Agreement), any subordination agreements, the Collateral Documents, any intercreditor agreement entered into in connection with the Loan from time to time, and all documents, instruments and agreements delivered in connection with the foregoing, all as amended, modified, supplemented, substituted, extended or renewed from time to time, are referred to collectively as the “Loan Documents.” As collateral security for Borrower’s obligations under the Loan Documents, Borrower and SWK entered into an Intellectual Property Security Agreement, dated as of March 4, 2022 (the “Intellectual Property Security Agreement”), granting to the lenders party certain liens and security interests in certain IP Collateral (as defined in the Intellectual Property Security Agreement), including the Intellectual Property identified on Schedule I attached hereto;

WHEREAS, the Intellectual Property Security Agreement was recorded with the United States Patent and Trademark Office (“USPTO”) against patent assets on March 11, 2022 at Reel 059237 and Frame 0638;

WHEREAS, the Intellectual Property Security Agreement was recorded with the USPTO against trademark assets on March 11, 2022 at Reel 007657 and Frame 0592;

WHEREAS, SWK entered into that certain Loan Purchase Agreement, dated as of June 16, 2023 (the “SWK LPA”), pursuant to which SWK sold all of its right, title and interests in and to the Loan and the other Loan Assets (as defined in the SWK LPA) to NANTAHALA CAPITAL MANAGEMENT, LLC a Massachusetts limited liability company (“NCM”), and NCM purchased and assumed all of SWK’s right, title and interests in and to the Loan and such other Loan Assets. In connection therewith, NCM and SWK executed that certain Assignment and Acceptance Agreement, dated as of June 16, 2023 (the “SWK Assignment Agreement”), pursuant to which SWK assigned to NCM all of SWK’s and Lenders’ right, title, and interest in, to, and under the Loan, the Loan Assets and the Loan Documents, and NCM agreed to perform and assume all such rights and interests with respect to the Loan;

WHEREAS, the SWK Assignment Agreement was recorded with the USPTO against patent assets on July 6, 2023 at Reel 064167 and Frame 0828;

WHEREAS, Zevra entered into that certain Loan Purchase Agreement, dated as of August 30, 2023 (the “Zevra LPA”), pursuant to which NCM sold all of its right, title and interests in and to the Loan and the other Loan Assets (as defined in the Zevra LPA) to Zevra, and Zevra purchased and assumed all of NCM’s right, title and interests in and to the Loan and such other Loan Assets;

WHEREAS, pursuant to Section 15.4 of the Zevra LPA, NCM has assigned its rights, duties and obligations to Zevra as Successor Agent (as defined in the Zevra LPA), including the right to terminate and

release Lenders' liens and security interests in Borrower's right, title and interest in, to and under the IP Collateral.


NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which the parties acknowledge Zevra, as Successor Agent, hereby releases, terminates and discharges the liens and security interests granted to the Lenders under the Loan Documents, the SWK LPA, and the Zevra LPA with respect to Borrower's right, title, and interest in the IP Collateral and all proprietary rights relating to or arising from such IP Collateral including, without limitation, Borrower's right, title, and interest in and to the IP Collateral and proprietary rights identified on Schedule I attached hereto and made part hereof, and any right, title or interest of the Lenders arising under the Loan Documents, the SWK LPA, and the Zevra LPA in and to the IP Collateral shall hereby terminate, cease and become void. The Borrower affirms Zevra's right to, as Successor Agent, and Zevra hereby consents to the recording of this Release with the USPTO and agrees to duly execute and deliver any further documents and do such other acts as may be reasonably necessary, at Zevra's cost and expense, to effect the release of the security interest with respect to the IP Collateral as contemplated hereby. All capitalized terms used in this Release and not defined herein, have the meanings ascribed to such terms in the Loan Documents, the SWK LPA, and the Zevra LPA.

This Release shall be governed by, and construed in accordance with, the laws of the State of New York.


[SIGNATURE PAGE FOLLOWS]

IN **WITNESS WHEREOF**, the undersigned has caused this Release to be duly executed as of the date first written above.

ZEVRA THERAPEUTICS, INC., as the Successor Agent

DocuSigned by:

By: _____
Name: R. LaDuane Clifton
Title: Chief Financial Officer, Secretary and Treasurer

ACER THERAPEUTICS INC., as Borrower

DocuSigned by:

By: _____
Name: R. LaDuane Clifton
Title: Chief Financial Officer, Secretary and Treasurer

[Signature Page to Termination and Release of Security Interests]

PATENT
REEL: 067020 FRAME: 0041


Schedule I

Intellectual Property

(See Attached)

Trademarks - January 2022

Case Reference	Next Upcoming Action Due	Deadline	Country	Mark	Status	Serial No.	Filing Date	Publication No.	Publication Date	Registration No.	Registration Date	Renewal date
51078-T02BR2	Renewal Fee	12/4/2028	BR - Brazil	EDSIVO	Registered	913319473	8/31/2017	913319473	9/19/2017	913319473	12/4/2018	12/4/2028
51078-T02CA2	Renewal Fee	7/29/2030	CA - Canada	EDSIVO	Registered	1,855,144	8/30/2017	1,855,144	10/24/2018	1,080,814	7/29/2020	7/29/2030
51078-T08001	File Statement of Use/Re-file	4/23/2022	US - United States	EDSIVO	Allowed	88/169,217	10/25/2018	-	2/26/2019	-	-	-
51078-T14WO2	Renewal Fee	8/25/2030	WIPO - Madrid Protocol (Designations: AU - Australia, BR - Brazil, CA - Canada, CH - Switzerland, CO - Columbia, EM - European Union, GB - United Kingdom, JP - Japan, KR - Korea, MX - Mexico, and TR - Turkey)	OLPRUVA	Registered in WIPO (Not yet registered in all designated countries/regions)	A0098587	8/25/2020	-	-	1553814	8/25/2020	8/25/2030
51078-T12001	File Extension/Statement of Use	2/16/2022	US - United States	OLPRUVA	Allowed	88/814,846	2/28/2020	-	6/23/2020	-	-	-
51078-T13001	File Extension/Statement of Use	2/16/2022	US - United States	ZEVVEZ	Allowed	88/814,853	2/28/2020	-	6/23/2020	-	-	-
51078-T14001	File Extension/Statement of Use	7/4/2022	US - United States	MIX-AID	Allowed	90/559,398	3/4/2021	-	11/9/2021	-	-	-
51078-T14WO2	Renewal Fee	9/2/2031	WIPO - Madrid Protocol (Designations: AU - Australia, BR - Brazil, CA - Canada, CH - Switzerland, CN - China, CO - Columbia, EM - European Union, GB - United Kingdom, JP - Japan, KR - Korea, MX - Mexico, NZ - New Zealand, and TR - Turkey)	MIX-AID	Registered in WIPO (Not yet registered in all designated countries/regions)	A0113167	9/2/2021	-	-	1619736	9/2/2021	9/2/2031



IP Status Chart

Prepared: February 10th, 2022
PRIVILEGED & CONFIDENTIAL

I. ACER-001

A. Formulation / Composition of Matter

Case Description and Number	Next Upcoming Action Due	Deadline	Country	Application Type	Status	Serial No.	Filing Date	Publication Date	Patent No.	Issue Date	Expiration date
PALATABLE COMPOSITIONS INCLUDING SODIUM PHENYLBUTYRATE AND USES THEREOF											
51078-003003	Maintenance Fee	10/16/2024	US - United States		Issued				11,154,521	10/26/2021	2036
51078-003005	Maintenance Fee	12/21/2024	US - United States		Issued				11,202,767	12/21/2021	2036
51078-003AU2	Annuitiy Payment	10/17/2021	AU - Australia	National Stage	Published	2016398029	10/17/2016	10/11/2018	-	-	-
51078-003AU2 51078-003BH2	Request Examination	10/17/2021	AU - Australia BH - Bahrain	National Stage	Published	2016398029	10/17/2016	10/11/2018	-	-	-
	Awaiting action by Bahraini Patent Office	-		National Stage	Pending	166/2018	10/17/2016	-	-	-	-
51078-003BR2	Awaiting response by Brazilian Patent Office	-	BR - Brazil	National Stage	Published	BR112018068665-4	10/17/2016	2/5/2019	-	-	-
51078-003BR2 51078-003CA2	Annuitiy Payment	10/17/2021	BR - Brazil CA - Canada	National Stage	Published	BR112018068665-4	10/17/2016	2/5/2019	-	-	-
	Annuitiy Payment	10/17/2021		National Stage	Published	3,017,573	10/17/2016	9/21/2017	-	-	-
51078-003CA2 51078-003EP2	Request Examination	10/17/2021	CA - Canada EP - Europe	National Stage	Published	3,017,573	10/17/2016	9/21/2017	-	-	-
	Reply to Office Action	5/5/2021		National Stage	Published	16894786.9	10/17/2016	1/23/2019	-	-	-
51078-003EP2 51078-003IL2	Annuitiy Payment	10/17/2021	EP - Europe IL - Israel	National Stage	Published	16894786.9 261777	10/17/2016 10/17/2016	1/23/2019 10/31/2018	- -	- -	- -

Confidential

	Awaiting response by Israeli Patent Office	-		National Stage							
Case Description and Number	Next Upcoming Action Due	Deadline	Country	Application Type	Status	Serial No.	Filing Date	Publication Date	Patent No.	Issue Date	Expiration date
51078-003JP2	Reply to Office Action	7/6/2021	JP - Japan	National Stage	Published	2019-500212	10/17/2016	4/4/2019	-	-	-
51078-003KR2	Request Examination	10/17/2021	KR - Republic of Korea	National Stage	Published	10-2018-7029452	10/17/2016	1/25/2019	-	-	-
51078-003KW2	Annuity Payment	1/1/2021	KW - Kuwait	National Stage	Pending	PCT/139/2018	10/17/2016	-	-	-	-
51078-003MX2	Awaiting response by Mexican Patent Office	1/24/2021	MX - Mexico	National Stage	Published	MX/a2018/011229	10/17/2016	6/13/2019	-	-	-
51078-003NZ2	Annuity Payment	10/17/2021	NZ - New Zealand	National Stage	Pending	746866	10/17/2016	-	-	-	-
51078-003NZ2	Request Examination	10/17/2021	NZ - New Zealand	National Stage	Pending	746866	10/17/2016	-	-	-	-
51078-003OM2	Annuity Payment	10/17/2021	OM - Oman	National Stage	Pending	OM/P/2018/00274	10/17/2016	-	-	-	-
51078-003QA2	Annuity Payment	10/17/2021	QA - Qatar	National Stage	Pending	QA/201809/00400	10/17/2016	-	-	-	-
51078-003SA2	Reply to Office Action	6/8/2021	SA - Saudi Arabia	National Stage	Pending	518400020	10/17/2016	-	-	-	-
51078-003AE2	Annuity Payment	10/17/2021	AE - United Arab Emirates	National Stage	Pending	P6001296/2018	10/17/2016	-	-	-	-
51078-003001	Expired	-	US - United States	Provisional	Expired	62/308,614	3/15/2016	-	-	-	-
51078-003WO2	Expired	-	WO - Patent Cooperation Treaty	PCT	National Phase	PCT/US2016/057415	10/17/2016	9/21/2017	-	-	-
51078-003003	Awaiting action by US Patent Office	-	US - United States	Continuation	Published	16/746,186	1/17/2020	8/20/2020	-	-	-
51078-003004	Awaiting action by US Patent Office	-	US - United States	Continuation	Pending	17/196,416	3/9/2021	-	-	-	-
51078-003005	Awaiting action by US Patent Office	-	US - United States	Continuation	Pending	17/196,599	3/9/2021	-	-	-	-

Confidential

B. Methods of Use – MSUD (Licensed from Baylor College of Medicine)

Appl. No.	Appl. Date	Matter No.	Title	Case Status (Internal)	Reg. No.	Reg. Date	Country
10803013.1	7/26/2010	1000340505	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Austria
10803013.1	7/26/2010	1000342292	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Belgium
10803013.1	7/26/2010	1000208589	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Switzerland
10803013.1	7/26/2010	1000208588	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Germany
10803013.1	7/26/2010	1000175619	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Denmark
10803013.1	7/26/2010	1000354396	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Spain
10803013.1	7/26/2010	1000204918	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	France
10803013.1	7/26/2010	1000204917	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	United Kingdom
10803013.1	7/26/2010	1000342293	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Ireland
10803013.1	7/26/2010	1000340517	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Italy
10803013.1	7/26/2010	1000362920	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Luxembourg
10803013.1	7/26/2010	1000175630	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Monaco

10803013.1	7/26/2010	1000204919	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Netherlands
10803013.1	7/26/2010	1000317155	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	EP Granted - Nationalized	2456304	8/19/2015	European Patent Office
15173016.5	7/26/2010	1000354395	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Abandoned			European Patent Office
16174310.9	7/26/2010	1000198683	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Abandoned			European Patent Office
10803013.1	7/26/2010	1000342295	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Portugal
10803013.1	7/26/2010	1000208590	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Sweden
10803013.1	7/26/2010	1000354397	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	2456304	8/19/2015	Turkey
13/386549	7/26/2010	1000003157	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	9078865	7/14/2015	United States of America
14/745205	7/26/2010	1000204261	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	9737499	8/22/2017	United States of America
15/653155	7/18/2017	1000173420	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Issued	10092532	10/9/2018	United States of America
16/134558	9/18/2018	1001047360	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Abandoned			United States of America
16/740131	1/10/2020	1001108069	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Application Filed			United States of America
61/228485	7/24/2009	11007293	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Expired			United States of America
PCT/US2010/043240	7/26/2010	11007293	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	Expired			Patent Cooperation Treaty

C. ACER-001 Methods of Use

C&E Reference	Next Upcoming Action Due	Deadline	Country	Application Type	Status	Serial No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date	Expiration date
---------------	--------------------------	----------	---------	------------------	--------	------------	-------------	-----------------	------------------	------------	------------	-----------------

ADMINISTRATION OF SODIUM PHENYLBUTYRATE IN A FASTED STATE TO TREAT UREA CYCLE DISORDERS

51078-011001	PCT deadline	7/7/2021	US - United States	Provisional	Expired	63/048,892	7/7/2020	-	-	-	-	-
51078-011WO2	Reply to International Search Report	5/7/2022	WO - Patent Cooperation Treaty	PCT	Pending	PCT/US2021/040760	7/7/2021					

METHODS OF ADMINISTERING TASTE MASKED PHENYLBUTYRATE

51078-012001	PCT deadline	8/13/2021	US - United States	Provisional	Expired	63/065,272	8/13/2020	-	-	-	-	-
--------------	--------------	-----------	--------------------	-------------	---------	------------	-----------	---	---	---	---	---

METHODS OF TREATING NITROGEN RETENTION AND OTHER DISORDERS

51078-015001	PCT deadline	4/9/2022	US - United States	Provisional	Pending	63/173,098	4/9/2021	-	-	-	-	-
--------------	--------------	----------	--------------------	-------------	---------	------------	----------	---	---	---	---	---

DOSAGE FORM FOR IMPROVING PALATABILITY OF DRUG SUBSTANCE – China Specific

51078-16CN2	Awaiting action by Chinese Patent Office		CN – China	Utility Model	Pending	202122004991.9	8/24/2021					
51078-16001	PCT deadline		US - United States	Provisional	Pending	63/232,011	8/11/2021					

II. Osanetant

A. Composition of Matter

Case Description and Number	Country	Upcoming Due Dates	Action Due	Application Status	App Number	Filing Date	Priority Dates	Assignee	Notes
SOLID FORMS OF OSANETANT) 60BB-332184-P	US	7/02/2022	File PCT/Utility Application	Provisional	63218211	7/02/2021		Acer Therapeutics, Inc.	Covers novel polymorphs and salts of osanetant

B. Methods of Use (Acer, Univ. Washington and Kansas)

Case Description and Number	Country	Upcoming Due Dates	Action Due	Application Status	App Number	Filing Date	Priority Dates	Assignee	Patent Number	Notes

Osanetant for treating Cancer Patients 60BB-310111-P/P2	US	7/30/2021	File PCT/Utility Application	Completed	63/059,086 63/134,542	7/30/2020 1/6/2021	7/30/2020	Acer Therapeutics Inc.		Co-owned with Univ. Washington
NK RECEPTOR ANTAGONISTS FOR CANCER PATIENTS 60BB-310111-WO	WO	02/03/2022	Utility - ORG	Published	PCT/US2021/044016 WO 2022/026900	7/30/2021	7/30/2020	Acer Therapeutics, Inc.		Co-owned with Univ. Washington
Osanetant for Contraception 60BB-314373-P	US	7/30/2021	File PCT/Utility Application	Completed	63/059,062	7/30/2020	7/30/2020	Acer Therapeutics Inc.		Acer Only
Osanetant for Contraception 60BB-314373-WO	WO	2/3/2022	Utility - ORG	Published	PCT/US2021/044018	7/30/2021	7/30/2020	Acer Therapeutics Inc.		
Osanetant for VMS	US	7/6/2021	Pay issue fee; file no fee continuation	Issued	16/114661	8/28/2018	12/3/12	University of Washington	11,083,726	Negotiating license. Claims currently directed to menopausal patients having short term estrogen therapy.

METHODS FOR TREATING PATIENTS HAVING LOW ESTROGEN WITH NK3	US	1/31/2023	File PCT/Utility Application	Pending	63/306,216	02/03/2022		Acer Therapeutics Inc.		Added more data/information to original filing of 1/31/22
60BB-337801-P2										
METHODS FOR TREATING PATIENTS WITH NK3 ANTAGONISTS	US	1/31/2023	File PCT/Utility Application	Pending	63/305,209	01/31/2022		Acer Therapeutics Inc.		

HAVING LOW ESTROGEN									
60BB-337801-P									
NK RECEPTOR ANTAGONISTS FOR TREATMENT OF PROSTATE CANCER	US	1/31/2023	File PCT/Utility Application	Pending	63/306,215	02/03/2022		Co-owned between Acer Therapeutics Inc. and University of Kansas	Co-owned with Kansas. Negotiating license
60BB-342333-P2									Added additional subject matter from Kansas to original filing of 1/31/22
NK RECEPTOR ANTAGONISTS FOR TREATMENT OF PROSTATE CANCER	US	1/31/2023	File PCT/Utility Application	Pending	63/305,207	01/31/2022		Acer Therapeutics Inc.	

A. Emory Univ License: Use of Osanetant PTSD

Case Description and Number	Country	Upcoming Due Dates	Action Due	Application Status	App Number/Patent Number	Filing Date/Issue Date	Priority Date	Assignee	Notes
Osanetant for PTSD	US	None	N/A	Granted	10,314,835	6/11/2019	06/25/14	Emory University	
Osanetant for conditioned fear	US	None	N/A	Pending	16/676,030	11/6/2019	06/25/14	Emory University	Response just filed; awaiting next action or Notice of Allowance
Osanetant for PTSD	EP	8/16/2020 (Real Deadline is 10/16/2020)		Granted	EP3160469	04/28/21	06/25/14	Emory University	Validated in France, UK, Germany, Italy, Spain, Switzerland, Ireland and the Netherlands

III. Celiprolol (EDSIVO®)

A. Methods of Use (Licensed from AP-HP)

Case Description and Number	Country	Upcoming Due Dates	Action Due	Application Status	App Number	Filing Date	Priority Dates	Assignee	Notes
Dosing Regimen									
Dosing Regimen 60BB-287147-AR	AR	None		Pending	20180103795	12/21/18	12/21/17	Assistance Publique-Hopitaux de Paris (AP-HP) Universite de Paris	
Dosing Regimen 60BB-287147-US2	US	07/15/2021	Assignment and Declaration Due	Published	16/930,208	07/15/20	12/21/17	Assistance Publique-Hopitaux de Paris (AP-HP)	Filed Track 1
Dosing Regimen 60BB-287147-BR	BR	12/19/2021 12/19/2021	Annuity Due Request Examination - Final	Published	BR112020012095-2	12/19/18	12/21/17	Assistance Publique-Hopitaux de Paris (AP-HP)	
Dosing Regimen	CA	12/19/2021 12/19/2023	Maintenance Fee	Pending	3083432	12/19/18	12/21/17	Assistance Publique-	

60BB-287147-CA			Request Examination - Final				Hopitaux de Paris (AP-HP)	
Dosing Regimen 60BB-287147-MX	MX			Pending	MX/a/2020/006351	12/19/18	12/21/17	Assistance Publique- Hopitaux de Paris (AP-HP)

Methods of Use: Pregnancy

Pregnancy 60BB-287148-AR	AR			Published	20180103794	12/21/18	12/21/17	Assistance Publique- Hopitaux de Paris (AP-HP) Universite de Paris	
Pregnancy 60BB-287148-US2	US	5/20/2021	Assignment and Declaration Due	Pending	16/879,511	05/20/20	12/21/17	Assistance Publique- Hopitaux de Paris (AP-HP) Universite de Paris	Awaiting Office Action, SMRH to handle deadline
Pregnancy 60BB-287148-BR	BR	12/19/2021	Annuity Due Request Examination - Final	Pending	BR112020012529-6	12/19/18	12/21/17	Assistance Publique- Hopitaux de Paris (AP-HP) Universite de Paris	
Pregnancy 60BB-287148-CA	CA	12/19/2021 12/19/2023	Maintenance Fee Request Examination - Final	Pending	3083407	12/19/18	12/21/17	Assistance Publique- Hopitaux de Paris (AP-HP) Universite de Paris	
Pregnancy 60BB-287148-MX	MX			Pending	MX/a/2020/006344	12/19/18	12/21/17	Assistance Publique- Hopitaux de Paris (AP-HP) Universite de Paris	

PATENT

REEL: 067020 FRAME: 0054

IV. Emetine

A. Covid and Composition of Matter

Case Description and Number	Country	Upcoming Due Dates	Action Due	Application Status	App Number	Filing Date	Priority Date	Assignee	Notes
60BB-314393-WO	US	9/26/2022	Deadline for National Phase Filing	Pending	PCT/US2021/024399	3/26/2021	3/26/2020	Acer Therapeutics Inc. The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Emetine for Sars-Cov2 Uses
SOLID FORMS OF EMETINE 60BB-322499-P	US	12/4/2021	Deadline for filing US and PCT applications	Completed	63/121,743	12/4/2020	12/4/2020	Acer Therapeutics, Inc.	Polymorph application
60BB-322499-WO	WO			Pending	PCT/US2021/061867	12/03/2021	12/4/2020	Acer Therapeutics Inc.	Polymorph application
60BB-322499-US	US			Pending	17/542,165	12/03/2021	12/4/2020	Acer Therapeutics Inc.	Polymorph application

PATENT
7020 FRAME: 0056

Confidential